The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections
Because weight loss is not only about medication but also about lifestyle changes, some people may remain on Semaglutide longer under guidance
doi:10.1056/NEJMoa2032183 Lempesis IG, Liu J, Dalamaga M
The TRIUMPH phase 3 development program is testing the efficacy of retatrutide for obstructive sleep apnea (OSA), osteoarthritis, and weight management
For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with improved long-term graft survival and overall survival, according to study data